Johnson & Johnson JNJ
$276.22 +$3.90 (+1.43%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $276.00 -0.08%
Open$267.56
Prev close$272.32
Day range$265.55 – $276.41
Volume8.86M
Market cap$664.95B
P/E (TTM)42.0
Dividend yield1.91%
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Institutional ownership76.5%+0.29 pts vs. prior quarter
Institutions holding5,363+30 vs. prior quarter
Insider trades (recent)27 buys / 20 sellsNet buying
Short interest0.70% of floatDays to cover 2.0 · as of 15 Oct 2026
Short-sale volume share9.8%5-day average of daily volume
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$142.67M (8 inflow days, 12 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 26.9% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 1.05% to 0.70% of float over the last 6 biweekly reports (31 Jul 2026 to 15 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +1,051,362 | 0.1% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +6,508,457 | 1.0% |
| Fisher Investments | Mutual Fund | 2026/Q3 | +4,043,445 | 0.6% |
| Wellington Management Group | Mutual Fund | 2026/Q3 | +2,513,321 | 0.9% |
| Capital Research | Mutual Fund | 2026/Q3 | +2,336,969 | 1.1% |
| SG Americas Securities, LLC | Private Company | 2026/Q3 | +1,269,232 | 0.2% |
| Deutsche Asset & Wealth Management | Mutual Fund | 2026/Q3 | +1,222,179 | 0.6% |
| Citigroup Inc. | Public Company | 2026/Q3 | +1,092,689 | 0.2% |
| The Goldman Sachs Group, Inc. | Public Company | 2026/Q3 | +1,069,846 | 0.2% |
| Hudson River Trading LLC | Private Company | 2026/Q3 | +1,031,961 | 0.0% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +902,292 | 0.1% |
| AGF Management Limited | Mutual Fund | 2026/Q3 | +887,557 | 0.1% |
| Invesco Capital Management LLC | Mutual Fund | 2026/Q3 | +873,516 | 0.3% |
| TD Asset Management | Mutual Fund | 2026/Q3 | +870,065 | 0.2% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +856,380 | 2.7% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 7 Sep 2026 | Marillyn Hewson | Lead Independent Director | Other Derivative Acquisition | +180 | – | 16,049 |
| 7 Sep 2026 | Eugene Woods | Independent Director | Other Derivative Acquisition | +135 | – | 6,579 |
| 7 Sep 2026 | Daniel Pinto | Director | Other Derivative Acquisition | +113 | – | 2,445 |
| 1 Sep 2026 | Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | Derivative Exercise and Sale | -33,597 | $274.74 | 26,251 |
| 31 Aug 2026 | Tom Cavanaugh | Executive VP & Worldwide Chairman of Innovative Medicine | Initial Statement of Beneficial | +0 | – | 5,337 |
| 16 Aug 2026 | Jennifer Taubert | Former Executive VP & Worldwide Chairman of Innovative Medicine | Derivative Exercise and Sale | -15,000 | $263.36 | 194,451 |
| 12 Aug 2026 | Joaquin Duato | Chairperson & CEO | Derivative Exercise and Sale | -123,291 | $262.00 | 307,837 |
| 5 Aug 2026 | Elizabeth Forminard | Chief Legal Officer | Open Market Disposition | -6,574 | $255.93 | 16,994 |
| 5 Aug 2026 | Elizabeth Forminard | Chief Legal Officer | Derivative Exercise and Sale | -9,344 | $257.76 | 16,994 |
| 4 Aug 2026 | Joaquin Duato | Chairperson & CEO | Open Market Disposition | -48,480 | $258.74 | 307,837 |
| 19 Jul 2026 | Vanessa Broadhurst | Executive Vice President of Global Corporate Affairs | Derivative Exercise and Sale | -23,054 | $251.27 | 23,003 |
| 10 Jun 2026 | Kathryn Wengel | Executive VP and Chief Technical Operations & Risk Officer | Derivative Exercise and Sale | -10,000 | $241.15 | 114,659 |
| 8 Jun 2026 | Marillyn Hewson | Lead Independent Director | Other Derivative Acquisition | +214 | – | 15,792 |
| 8 Jun 2026 | Eugene Woods | Independent Director | Other Derivative Acquisition | +161 | – | 6,412 |
| 8 Jun 2026 | Daniel Pinto | Director | Other Derivative Acquisition | +134 | – | 2,321 |
| 30 Apr 2026 | John Reed | Executive Vice President of Innovative Medicine and R&D | Derivative Exercise and Sale | -11,002 | $229.85 | 24,911 |
| 30 Apr 2026 | John Reed | Executive Vice President of Innovative Medicine and R&D | Derivative Exercise and Retained | +14,253 | – | 24,911 |
| 22 Apr 2026 | John Morikis | Director | Other Derivative Acquisition | +1,540 | – | 1,540 |
| 22 Apr 2026 | Hubert Joly | Independent Director | Other Derivative Acquisition | +975 | – | 9,184 |
| 22 Apr 2026 | Marillyn Hewson | Lead Independent Director | Other Derivative Acquisition | +975 | – | 15,488 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 16,766,729 | 0.7% | 2.0 |
| 30 Sep 2026 | 22,070,973 | 0.9% | 3.3 |
| 15 Sep 2026 | 21,188,522 | 0.9% | 3.7 |
| 31 Aug 2026 | 21,670,595 | 0.9% | 3.3 |
| 14 Aug 2026 | 21,591,738 | 0.9% | 3.3 |
| 31 Jul 2026 | 25,408,119 | 1.1% | 3.0 |
No comments yet — be the first to weigh in on JNJ.
Sign in to join the discussion.